GlassScriptPhysician profile
Saeid Nosrati
NPI 1245266618
$10,925.30
in general payments reported to CMS, 2019-2025
10 companies · $29.00 in 2025
The $29.00 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,695 · 2020: $433 · 2021: $200 · 2022: $223 · 2023: $636 · 2024: $3,710 · 2025: $29.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,000 · Food and Beverage: $1,160 · Travel and Lodging: $133 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $68.00 · Education: $13.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,000.00 |
| Food and Beverage | $1,160.23 |
| Travel and Lodging | $133.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $68.00 |
| Education | $13.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $5,653.52 | 2019-2023 | |
| Calliditas Therapeutics US INC. | $3,269.48 | 2023-2024 | Tarpeyo |
| Horizon Therapeutics Plc | $607.03 | 2022-2023 | Uplizna |
| Vifor (International) LTD. | $433.33 | 2020 | |
| Amgen INC. | $345.77 | 2024 | Uplizna |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| Alexion Pharmaceuticals, INC. | $150.00 | 2019 | |
| Abbvie INC. | $108.17 | 2024 | |
| Glaxosmithkline, LLC. | $90.00 | 2022 | |
| Becton, Dickinson and Company | $68.00 | 2023-2025 | Power-Trialysis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saeid Nosrati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.